Capital owners would much prefer running stuff locally Empirically that's not the case. There are plenty of tales of outsourcing in pharma going wrong, yet the

Capital owners would much prefer running stuff locally Empirically that's not the case. There are plenty of tales of outsourcing in pharma going wrong, yet the stock market rewards contracting out to CROs over doing stuff in-house. Recently: https://chemistryjobs.acs.org/job/29501/associate-director-drug-discovery-outsourcing- https://chemistryjobs.acs.org/job/29501/associate-director-d... Director of Outsourcing in Discovery. In Discovery. That's not even a cost center, the real costs are incurred later in the pipeline, at that stage you want to keep the life scientists, the structure guys and the synthetic chemists all in one building. But Genentech are now part of Roche and a public company needs to keep an eye on the stock market.